ESPE Abstracts (2019) 92 P3-127

Rosuvastatain Therapy in Children with Heterozygous Familial Hypercholesterolemia, Efficacy, and Security of Low Régimen of Therapy

Shokery Awadalla


Pediatric Endocrinology, Bogota, Colombia


Introduction: Heterozygous familial hypercholesterolemia is as frequent as 1: 200-500, and the mortality risk is four times more than unaffected children.Nutritional therapy in addition to physical activity can help but is not enough to avoid later morbidity and mortality. Stations have shown efficacy in children, but we do not have enough data for long term safety.

Aim: to compare tow regimens of therapy using rosuvastatain 10 mg ; once daily and the other once every other day. observation period was 6 months

Methods: 46 children with ages between 10- 15 years, without obesity or other hormonal diseases, were assigned randomly to one of two groups;

Group 1: 10 mg / daily

Group 2: 10 mg every other day

Basal lipids were registered and every three months twice during the study

Nutritional recommendations and physical activity were given to both groups.

Results: 23 children were included in each group. basal lipid levels were comparable in both groups before therapy.Group 1 with daily therapy showed decrease of CT And LDL more than the group 2 but not Statistically significant. No one shows elevated liver enzymes or muscle pain. Values are reported en mg/dl.

Table 1. Values of basal lipids and of each gruop after therapy
Total CholesterolLDLHDLTG
Basal26620242110
Gruop 1150835181
Group 21681004899

Conclusiones: Rosuvastatin therapy every other day can be of comparable efficay as daily therap in mangement of eleveted cholesterol levels in children . Being a lifelong therapy, every other day régimen can be used with iqual efficacy and probably with menor side effects in children.

Article tools

My recent searches

No recent searches.